Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Colestipol

Mohammed Hamzah Hameed  1 , Preeti Patel, Khashayar Farzam  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Colestipol

Mohammed Hamzah Hameed et al.
Free Books & Documents

Excerpt

Colestipol is an antihyperlipidemic drug approved by the United States Food and Drug Administration (FDA) as an adjunctive therapy to lower elevated low-density lipoprotein cholesterol in patients with primary hypercholesterolemia unresponsive to dietary modifications alone. The drug can be used as monotherapy or in conjunction with a statin, niacin, or ezetimibe. Colestipol is a cholesterol-lowering drug that reduces the risk of coronary artery disease. This drug belongs to the class of bile acid sequestrants and is one of the earliest drugs used for this purpose. However, the current predominant application involves providing supplementary therapy, especially in cases where statins or alternative lipid-lowering agents prove inadequate in sufficiently reducing cholesterol levels.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Mohammed Hamzah Hameed declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Khashayar Farzam declares no relevant financial relationships with ineligible companies.

References

    1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): 2017. Sep 28, Colestipol. - PubMed
    1. Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin BA, Caslake MJ, Colquhoun I, Wheatley DJ, Lorimer AR, Shepherd J. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1996 Feb;16(2):236-49. - PubMed
    1. Insull W, Davidson MH, Demke DM, Dujovne CA, Eckert SM, Ginsberg D, Goldberg AC, Hodis HN, Hughes TA, Kane JP. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995 Jan 20;112(2):223-35. - PubMed
    1. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res. 2002 Jun;51(6):715-21. - PubMed
    1. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233-40. - PubMed

Publication types

LinkOut - more resources